Mirum Pharmaceuticals broadens expanded access program for maralixibat in Alagille syndrome to Europe and Australia

Maralixibat is an apical sodium dependent bile acid transporter inhibitor being evaluated for the treatment of cholestatic pruritus in patients with Alagille syndrome. The expanded access (‘compassionate use’) program will be open to eligible patients in the UK.

Source:

Biospace Inc.